Featured Research

from universities, journals, and other organizations

Flu Shots Not To Be Sneezed At: Study Highlights Need To Educate High-risk Patients

Date:
October 23, 2009
Source:
Springer
Summary:
Two in five at-risk American adults who would benefit from vaccination against flu are missing out on the shots because they believe they do not need them, according researchers. Their work shows that asking simple questions about the intention to be protected against flu may be an effective way to increase its uptake.

Two in five at-risk American adults who would benefit from vaccination against seasonal flu are missing out on the protective shots because they believe they do not need them and are not inclined to be vaccinated. And among those who say they do intend to take up the vaccine, nearly half get around to it, according to Dr. Katharine Harris from the RAND Corporation in Arlington, USA, and her team.

Their work shows that asking simple questions about the intention to be protected against flu may be an effective way of identifying those patients who are likely to benefit from further information and discussion about the benefits of the vaccine, in order to increase its uptake. Their findings are published online this week in the Journal of General Internal Medicine, published by Springer.

Despite strong evidence that seasonal influenza vaccines are effective and safe, uptake of the vaccine among adults in the US falls short of targets. Dr. Harris and colleagues assessed whether asking unvaccinated individuals about their intentions to be vaccinated against seasonal flu predicted actual vaccination. They also looked at concerns about, and barriers to, vaccination as well as willingness to be vaccinated based on a recommendation by a health care provider.

The researchers analyzed data from two surveys covering over 1,500 American adults to measure the uptake of the vaccine and understand intentions and motivations for being vaccinated. The individuals surveyed fell into the high risk groups specifically recommended for vaccination by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Harris and team found that by midseason, over a third of adults for whom the influenza vaccine was specifically recommended had been vaccinated, and another 17 percent said they intended to do so by the end of the season. Just over half of those who intended to be vaccinated followed through. However, nearly 45 percent of adults surveyed did not intend to be vaccinated at midseason and almost all remained unvaccinated by the end of the season.

Adults who had no intention of being vaccinated were more likely to cite a perceived lack of need as the main reason for not being vaccinated. Nonetheless, a substantial proportion of these individuals expressed willingness to be vaccinated based on a strong recommendation from a health care provider. Those who intended to be vaccinated said that the main reason they had not yet taken up the vaccine was because they had not got around to it.

The authors conclude: "Making vaccination convenient to those who intend to be vaccinated by administering influenza vaccines onsite, or by offering practical advice about where and when to be vaccinated, might be effective in helping millions of additional adults to be vaccinated who would otherwise not be. Persuading the two in five adults recommended for seasonal influenza vaccine who are not inclined to be vaccinated is likely to pose a substantially greater challenge and will likely require changing patients' fundamental beliefs about the benefits and risks of the vaccine."


Story Source:

The above story is based on materials provided by Springer. Note: Materials may be edited for content and length.


Journal Reference:

  1. Harris et al. Do People Who Intend to Get a Flu Shot Actually Get One? Journal of General Internal Medicine, 2009; DOI: 10.1007/s11606-009-1126-2

Cite This Page:

Springer. "Flu Shots Not To Be Sneezed At: Study Highlights Need To Educate High-risk Patients." ScienceDaily. ScienceDaily, 23 October 2009. <www.sciencedaily.com/releases/2009/10/091022114353.htm>.
Springer. (2009, October 23). Flu Shots Not To Be Sneezed At: Study Highlights Need To Educate High-risk Patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/10/091022114353.htm
Springer. "Flu Shots Not To Be Sneezed At: Study Highlights Need To Educate High-risk Patients." ScienceDaily. www.sciencedaily.com/releases/2009/10/091022114353.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins